Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor VIII/von Willebrand factor - Octapharma

Next Previous
Drug Profile

Factor VIII/von Willebrand factor - Octapharma

Alternative Names: Eqwilate; Human factor VWF/FVIII concentrate; Wilate

Latest Information Update: 29 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIII replacements; Von Willebrand factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A; Von Willebrand disease

Most Recent Events

  • 18 Dec 2024 Octapharma completes a phase-III trial in Von Willebrand disease (In children, In infants, In neonates) in Ukraine, Russia, Macedonia, Moldova, Czech Republic, Belarus, Germany and USA (IV) (NCT04953884), (EudraCT2020-004344-28)
  • 22 Jan 2024 Adverse events and efficacy data from a phase III WIL-31 trial von Willebrand Disease were released by the Deciphera Pharmaceuticals
  • 12 Dec 2023 Launched for Von Willebrand disease (In adolescents, In children, In adults) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top